Cambridge, 6 March 2017 ... The number of users of the Repositive platform has now reached over 1000 globally, which includes users from pharma, biotech and academia.
Repositive is a software company developing novel tools to improve discovery and access to human genomic data, offering a free-to-subscribe online platform for scientific researchers. The platform, a community-driven marketplace indexing worldwide genomic data sources through a single portal, allows its users to quickly identify the best data available for their research.
Repositive platform users not only benefit from the access to the largest portal for human genomic data, but also from the interactions with peer scientists with data interest and from the specialised collections of data. The latest collections include population genetics, epigenetics, microbiome and personal genomic data. The Repositive platform now boasts over 1,000,000 datasets including data from sources like ExAC, SRA, dbGaP, along with a number of data sources for personal and population genomes including Mike Lin’s genome, The Corpasome, The Genome of the Netherlands and The 1000 Genomes.
Dr Arindam Basu from the University of Canterbury, and a Repositive platform user added:
“I greatly appreciate the flexibility and ease with which Repositive.io enables search for gene and phenotype data and make both types of data accessible. Further, Repositive also makes it easy to access restricted data and even connect to teams who share data. I recently used Repositive site to access the Chinese Kadoori Project dataset. This not only enabled me to access their datasets and learn their protocols of accessing the data, it also made it easy for me to apply for and establish mutual collaboration with the researchers. I would not have known of this opportunity had I not used Repositive.io"
Fiona Nielsen, CEO of Repositive, said:
“This is a significant milestone for Repositive. Passing the 1000 users mark in the first month of the new year and the increasing activity of the Repositive community illustrates the strength and utility of the platform. As we prepare to bring on more community-driven features and offer premium subscriptions later this year, our engaged user base across both academia and industry shows the how Repositive is becoming a standard tool in the research workflow.”
2016 saw Repositive make significant steps with a number of major partnerships with large pharma companies secured, including AstraZeneca, Boehringer Ingelheim, Merck Group and Horizon Discovery.